(NASDAQ: IMCR) Immunocore Holdings's forecast annual revenue growth rate of 10.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.45%.
Immunocore Holdings's revenue in 2026 is $430,775,000.On average, 18 Wall Street analysts forecast IMCR's revenue for 2026 to be $23,450,410,237, with the lowest IMCR revenue forecast at $21,903,391,782, and the highest IMCR revenue forecast at $25,117,420,469. On average, 17 Wall Street analysts forecast IMCR's revenue for 2027 to be $25,769,907,947, with the lowest IMCR revenue forecast at $17,437,946,702, and the highest IMCR revenue forecast at $32,493,052,396.
In 2028, IMCR is forecast to generate $30,617,472,765 in revenue, with the lowest revenue forecast at $15,608,200,840 and the highest revenue forecast at $45,719,442,200.